I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision ...

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Leerink Partnrs issued their Q1 2025 EPS estimates for Blueprint Medicines in a research note issued on Thursday, February ...

Explore Repligen's Q4 2024 earnings insights, highlighting strong non-COVID growth, standout CDMO performance, innovative product launches, and ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...